BioSpace News Archive

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported results for the fourth quarter and full year ended December 31, 2020.

SQZ Biotech, a cell therapy company developing novel treatments for multiple therapeutic areas, reported full year 2020 financial results and recent business highlights.

After launching highly successful managed testing programs for colleges, GENETWORx leverages testing program expertise and capacity to help K-12 schools

Agios Pharmaceuticals, Inc., a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, announced it will sponsor Citizen Scientist: Unpacking the Science of Sickle Cell Disease, an initiative developed by the Sickle Cell Community Consortium to promote health literacy for sickle cell patients.

TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced the results of the 12-month analysis from the company’s post-market BRAVO study evaluating the clinical performance of OviTex Reinforced Tissue Matrix for the treatment of ventral hernias.

Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected by mid-year 2021 Interim data releases expected from PBCAR269A and PBCAR20A in 2021 Received FDA acceptance of IND application for PBCAR19B, a next-generation, stealth cell, anti-CD19 allogeneic CAR T candidate for non-Hodgkin lymphoma;

Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the appointment of Alexis A. Thompson, M.D., M.P.H., a world-renowned hematologist and sickle cell disease (SCD) expert, to the company’s board of directors.

U.S. Renal Care, a leading provider of dialysis services, who cares for more than 26,000 Americans living with kidney disease, announced its request that the Biden administration designate its 350+ care centers as COVID-19 vaccination points-of-dispensing for dialysis patients and their frontline care staff.

Prelude Corporation (PreludeDx ™ ), a leader in molecular diagnostics and precision medicine for early stage breast cancer, presented data at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer

Proprietary arenavirus immunotherapeutics platform demonstrated promising clinical activity with interim data from lead oncology and infectious disease candidates Follow-on offering strengthened cash basis with $143 million available at year-end to support progression of Human Papillomavirus 16-positive (HPV16+) cancer and Cytomegalovirus (CMV) programs and pipeline expansion HOOKIPA on track to report additional clinical data on efficacy and T cell response in 2021 for HB-201 and HB-202